taurine has been researched along with Anxiety Neuroses in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acamprosate was dosed at 1998 mg/day." | 6.75 | Acamprosate calcium as augmentation therapy for anxiety disorders. ( Costello, A; Raza, S; Schwartz, TL; Siddiqui, UA, 2010) |
| "The efficacy of pharmacological relapse prevention in alcoholism with acamprosate and naltrexone has been supported by several controlled trials." | 5.11 | Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. ( Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K, 2005) |
| "Acamprosate was dosed at 1998 mg/day." | 2.75 | Acamprosate calcium as augmentation therapy for anxiety disorders. ( Costello, A; Raza, S; Schwartz, TL; Siddiqui, UA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Helton, SG | 1 |
| Lohoff, FW | 1 |
| Schwartz, TL | 1 |
| Siddiqui, UA | 1 |
| Raza, S | 1 |
| Costello, A | 1 |
| Prisciandaro, JJ | 1 |
| Brown, DG | 1 |
| Brady, KT | 1 |
| Tolliver, BK | 1 |
| Kiefer, F | 1 |
| Helwig, H | 1 |
| Tarnaske, T | 1 |
| Otte, C | 1 |
| Jahn, H | 1 |
| Wiedemann, K | 1 |
| Litten, RZ | 1 |
| Allen, J | 1 |
| Fertig, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
2 reviews available for taurine and Anxiety Neuroses
| Article | Year |
|---|---|
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressi | 2015 |
Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.
Topics: Acamprosate; Alcohol Withdrawal Delirium; Alcoholism; Anxiety Disorders; Comorbidity; Depressive Dis | 1996 |
3 trials available for taurine and Anxiety Neuroses
| Article | Year |
|---|---|
Acamprosate calcium as augmentation therapy for anxiety disorders.
Topics: Acamprosate; Adult; Anti-Anxiety Agents; Anxiety Disorders; Drug Resistance; Drug Therapy, Combinati | 2010 |
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Bipolar Disorder; Comorbidity | 2011 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; | 2005 |